BioCentury | May 21, 2020
Finance

With repurposed antiviral, Atea draws $215M as it preps Phase II COVID-19 trial

...any damage until there’s a vaccine,” Sommadossi said. Sommadossi helped found two prior antiviral companies: Idenix Pharmaceuticals Inc....
BioCentury | Apr 9, 2020
Finance

As Tango moves toward clinic with $60M series B, another partnership could precede IPO

...she was also interim CFO at Neon Therapeutics Inc. (NASDAQ:NTGN), and was previously CFO of Idenix...
BioCentury | Nov 30, 2018
Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

...Inc. (NASDAQ:GILD) following its $11 billion acquisition in 2011. Mayers was EVP and CMO of Idenix Pharmaceuticals Inc....
...which Merck & Co. Inc. (NYSE:MRK) acquired for $3.9 billion in 2014. The pharma dropped Idenix's...
BioCentury | Nov 27, 2018
Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

...Inc. (NASDAQ:GILD) following its $11 billion acquisition in 2011. Mayers was EVP and CMO of Idenix Pharmaceuticals Inc....
...which Merck & Co. Inc. (NYSE:MRK) acquired for $3.9 billion in 2014. The pharma dropped Idenix's...
BioCentury | Oct 6, 2017
Clinical News

Merck discontinues HCV candidates MK-3682B and MK-3682C

...gained uprifosbuvir (MK-3682), a component of MK-3682B and MK-3682C, through its $3.9 billion acquisition of Idenix Pharmaceuticals Inc....
BioCentury | Oct 6, 2017
Clinical News

Merck discontinues HCV candidates MK-3682B and MK-3682C

...gained uprifosbuvir (MK-3682), a component of MK-3682B and MK-3682C, through its $3.9 billion acquisition of Idenix Pharmaceuticals Inc....
BioCentury | Sep 29, 2017
Clinical News

Merck discontinues HCV candidates

...gained uprifosbuvir (MK-3682), a component of MK-3682B and MK-3682C, through its $3.9 billion acquisition of Idenix Pharmaceuticals Inc....
BioCentury | Mar 3, 2017
Company News

Merck uprifosbuvir news

...pricing and the market opportunity." The pharma gained uprifosbuvir in its $3.9 billion acquisition of Idenix Pharmaceuticals Inc....
...trials of the uridine nucleotide analog HCV NS5B polymerase inhibitor would continue. When it acquired Idenix...
BioCentury | Feb 24, 2017
Company News

Merck takes haircut on Idenix asset

...its expectations for uprifosbuvir (MK-3862), which the pharma gained in its $3.9 billion acquisition of Idenix Pharmaceuticals Inc....
...trials of the uridine nucleotide analog HCV NS5B polymerase inhibitor would continue. When it acquired Idenix...
BioCentury | Dec 16, 2016
Company News

Jury awards Merck $2.5B in Gilead patent dispute

...2016. Idenix Pharmaceuticals Inc. filed the suit in 2013. Merck acquired Idenix in 2014. In its complaint, Idenix...
...for the District of Delaware. Gilead said it will challenge the outcome "vigorously," and that Idenix...
...and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) from Gilead (see BioCentury Extra, June 7) . Becky Simon Harvoni Sovaldi Gilead Sciences Inc. Idenix Pharmaceuticals Inc. Merck...
Items per page:
1 - 10 of 493
BioCentury | May 21, 2020
Finance

With repurposed antiviral, Atea draws $215M as it preps Phase II COVID-19 trial

...any damage until there’s a vaccine,” Sommadossi said. Sommadossi helped found two prior antiviral companies: Idenix Pharmaceuticals Inc....
BioCentury | Apr 9, 2020
Finance

As Tango moves toward clinic with $60M series B, another partnership could precede IPO

...she was also interim CFO at Neon Therapeutics Inc. (NASDAQ:NTGN), and was previously CFO of Idenix...
BioCentury | Nov 30, 2018
Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

...Inc. (NASDAQ:GILD) following its $11 billion acquisition in 2011. Mayers was EVP and CMO of Idenix Pharmaceuticals Inc....
...which Merck & Co. Inc. (NYSE:MRK) acquired for $3.9 billion in 2014. The pharma dropped Idenix's...
BioCentury | Nov 27, 2018
Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

...Inc. (NASDAQ:GILD) following its $11 billion acquisition in 2011. Mayers was EVP and CMO of Idenix Pharmaceuticals Inc....
...which Merck & Co. Inc. (NYSE:MRK) acquired for $3.9 billion in 2014. The pharma dropped Idenix's...
BioCentury | Oct 6, 2017
Clinical News

Merck discontinues HCV candidates MK-3682B and MK-3682C

...gained uprifosbuvir (MK-3682), a component of MK-3682B and MK-3682C, through its $3.9 billion acquisition of Idenix Pharmaceuticals Inc....
BioCentury | Oct 6, 2017
Clinical News

Merck discontinues HCV candidates MK-3682B and MK-3682C

...gained uprifosbuvir (MK-3682), a component of MK-3682B and MK-3682C, through its $3.9 billion acquisition of Idenix Pharmaceuticals Inc....
BioCentury | Sep 29, 2017
Clinical News

Merck discontinues HCV candidates

...gained uprifosbuvir (MK-3682), a component of MK-3682B and MK-3682C, through its $3.9 billion acquisition of Idenix Pharmaceuticals Inc....
BioCentury | Mar 3, 2017
Company News

Merck uprifosbuvir news

...pricing and the market opportunity." The pharma gained uprifosbuvir in its $3.9 billion acquisition of Idenix Pharmaceuticals Inc....
...trials of the uridine nucleotide analog HCV NS5B polymerase inhibitor would continue. When it acquired Idenix...
BioCentury | Feb 24, 2017
Company News

Merck takes haircut on Idenix asset

...its expectations for uprifosbuvir (MK-3862), which the pharma gained in its $3.9 billion acquisition of Idenix Pharmaceuticals Inc....
...trials of the uridine nucleotide analog HCV NS5B polymerase inhibitor would continue. When it acquired Idenix...
BioCentury | Dec 16, 2016
Company News

Jury awards Merck $2.5B in Gilead patent dispute

...2016. Idenix Pharmaceuticals Inc. filed the suit in 2013. Merck acquired Idenix in 2014. In its complaint, Idenix...
...for the District of Delaware. Gilead said it will challenge the outcome "vigorously," and that Idenix...
...and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) from Gilead (see BioCentury Extra, June 7) . Becky Simon Harvoni Sovaldi Gilead Sciences Inc. Idenix Pharmaceuticals Inc. Merck...
Items per page:
1 - 10 of 493